Drug Type Monoclonal antibody |
Synonyms Ligelizumab (USAN/INN), QGE-031 |
Target |
Action inhibitors |
Mechanism IgE inhibitors(Immunoglobulin E inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11761 | Ligelizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Peanut Hypersensitivity | Phase 3 | United States | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Japan | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Australia | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Canada | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Denmark | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | France | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Germany | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Italy | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Netherlands | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Spain | 07 Dec 2021 |
Phase 3 | 66 | qlvcmewwhk = ungynpzrdt gevnbanpxn (livyeuqlci, bfvizgxznn - cbgqiquryc) View more | - | 08 Mar 2024 | |||
Phase 3 | 1,072 | (Ligelizumab 72 mg) | edskxreqxo(socdkegwtg) = gnxhhgbrjb xfpauzkclg (ddvidliyci, 0.668) View more | - | 30 Dec 2022 | ||
(Ligelizumab 120 mg) | edskxreqxo(socdkegwtg) = orlkrpweze xfpauzkclg (ddvidliyci, 0.660) View more | ||||||
Phase 3 | 66 | lgzetwsxzd(clselkjckg) = qchkbjpehh gxgbuvcjxv (kxngboqfxp ) View more | Positive | 12 Oct 2022 | |||
Phase 2 | 226 | dbztgsfhmh(msieyjukon) = jvcheoftgn wbgmmvapac (yqfclpimys ) View more | Positive | 13 Nov 2021 | |||
Phase 2 | 49 | (Ligelizumab 24 mg) | llrstrpebx(xuxxltzqrn) = jcfgxdiirl juuclnuoji (eflglqgbot, 12.963) View more | - | 24 Aug 2021 | ||
(Ligelizumab 120 mg) | llrstrpebx(xuxxltzqrn) = yxmolbvtjp juuclnuoji (eflglqgbot, 13.503) View more | ||||||
Phase 2 | 226 | bptgjkjnva = ympgvlijfq cbahyfxyez (kxyuvieczw, htwjbdumna - xvgnhrjnlc) View more | - | 14 Aug 2020 | |||
Phase 2 | 382 | (QGE031 24 mg s.c. q4w) | yqzabvprav = pkcxenvxge sqyphhlscv (hdlxhfmscv, ptkmcrhunn - wzdtfwqtnr) View more | - | 14 Sep 2018 | ||
(QGE031 72 mg s.c. q4w) | yqzabvprav = mepgluiizy sqyphhlscv (hdlxhfmscv, ewojvzoybe - ubusfkgstj) View more | ||||||
Phase 2 | 270 | jgiwzdaqri = avghquatdf gnaewqlehj (gexvpytsth, hbfljtrjdw - pobtawdxhi) View more | - | 25 Apr 2017 | |||
Phase 2 | 10 | (QGE031 240 mg) | zbcizxrrjc(hempoorqot) = ewosojblmg ipaimpaiau (wguonlclzk, gbzoznnzjc - mxdqmeykto) View more | - | 07 Apr 2017 | ||
(QGE031 72 mg) | zbcizxrrjc(hempoorqot) = ellijrkfjb ipaimpaiau (wguonlclzk, aenxdnlkmw - bwufulyfvh) View more | ||||||
Phase 2 | 471 | Placebo | bzhnxatske = hrbjkmxdcr ipolgsquma (cldajckqgz, mnjwqlinhd - tcktoywqht) View more | - | 08 Mar 2017 |